Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

dc.date.accessioned2018-11-29T15:37:06Z
dc.date.accessioned2022-10-18T21:28:36Z
dc.date.available2018-11-29T15:37:06Z
dc.date.available2022-10-18T21:28:36Z
dc.date.created2018-11-29T15:37:06Z
dc.identifierhttp://hdl.handle.net/10533/228650
dc.identifier1140434
dc.identifierWOS:000347940900001
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4460006
dc.description.abstractSeveral recent pharmacogenetic studies have investigated the variability in both outcome and toxicity in cisplatin-based therapies. These studies have focused on the genetic variability of therapeutic targets that could affect cisplatin response and toxi
dc.languageeng
dc.relationhttps://www.frontiersin.org/articles/10.3389/fgene.2014.00391/full
dc.relationhandle/10533/111556
dc.relation10.3389/fgene.2014.00391
dc.relationhandle/10533/111541
dc.relationhandle/10533/108045
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.titleCan pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
dc.typeArticulo


Este ítem pertenece a la siguiente institución